reparixin

Reparixin is an orally available small molecule that acts as a non-competitive allosteric inhibitor of the CXC chemokine receptor type 1 (CXCR1) and 2 (CXCR2), which are receptors for interleukin 8 (IL-8 or CXCL8)[1][3][6]. By binding to these receptors, reparixin blocks IL-8-mediated signaling pathways involved in neutrophil recruitment, NETosis, and inflammatory responses[4][5]. This mechanism may reduce excessive inflammation and has potential antineoplastic effects by targeting cancer stem cells that overexpress CXCR1[3][6]. Reparixin has been investigated in clinical trials for conditions such as breast cancer, COVID-19 pneumonia, community-acquired pneumonia, delayed graft function after transplantation, adult respiratory distress syndrome (ARDS), myelofibrosis, polycythaemia vera, essential thrombocythaemia, fatigue related to cancer therapy, liver transplant rejection prevention and treatment of triple negative breast cancer[7]. The drug was originally developed by Dompe Farmaceutici.

Brand names

repertaxin

Other names

reparixin